GSC
SVA

Ground Swell Capital’s Sinovac Biotech, Ltd SVA Stock Holding History

Ground Swell Capital’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1K Sell
145
-32
-18% -$172 ﹤0.01% 2371
2014
Q2 		$1K Buy
+177
New +$1.07K ﹤0.01% 1973

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ground Swell Capital's SVA Position: Q3 2014 in Review

Ground Swell Capital reduced its Sinovac Biotech, Ltd (SVA) stake by 18% in Q3 2014, selling an estimated $172 and leaving 145 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2371.

Ground Swell Capital first reported a position in SVA in Q2 2014 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold SVA as of Q3 2014.

  • Ground Swell Capital held 145 shares of Sinovac Biotech, Ltd worth $1K as of Q3 2014.
  • Ground Swell Capital sold 32 Sinovac Biotech, Ltd shares in Q3 2014, an estimated $172.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Ground Swell Capital's portfolio in Q3 2014, its #2371 holding.
  • Ground Swell Capital first reported a position in Sinovac Biotech, Ltd in Q2 2014 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.